Premium
Hemodynamic, renal, and hormonal responses to alpha‐human atrial natriuretic peptide in patients with congestive heart failure
Author(s) -
Saito Hiroshi,
Ogihara Toshio,
Nakamaru Mitsuaki,
Hara Hiroko,
Higaki Jitsuo,
Rakugi Hiromi,
Tateyama Hitone,
Minamino Takazo,
Iinuma Kazushige,
Kumahara Yuichi
Publication year - 1987
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1987.124
Subject(s) - medicine , atrial natriuretic peptide , heart failure , plasma renin activity , aldosterone , blood pressure , cardiology , pulmonary wedge pressure , vascular resistance , hemodynamics , endocrinology , central venous pressure , renal blood flow , cardiac output , renin–angiotensin system , heart rate
Hemodynamic, renal, and hormonal effects of intravenous bolus injection of 50 µg synthetic α‐human atrial natriuretic peptide (α‐hANP) were studied in eight patients with congestive heart failure. α‐hANP caused significant reductions in mean blood pressure and systemic vascular resistance. These responses were sustained up to 90 minutes and not accompanied by reflex tachycardia. Cardiac index and stroke volume index increased significantly at 90 minutes and pulmonary capillary wedge pressure, pulmonary arterial pressure, and mean right atrial pressure remained unchanged. Urine volume, urinary sodium excretion, creatinine clearance, and fractional excretion of sodium increased significantly, but fractional excretion of potassium and phosphate did not change. Elevated plasma renin activity, plasma aldosterone, and norepinephrine were suppressed after the injection of α‐hANP. The bolus injection of this peptide has moderately hypotensive, vasorelaxant, and natriuretic effects in patients with congestive heart failure. Clinical Pharmacology and Therapeutics (1987) 42, 142–147; doi: 10.1038/clpt.1987.124